Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 1
2012 1
2013 2
2016 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
Bueno C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, Petazzi P, Martinez A, Rodriguez V, Vinyoles M, Cantilena S, Williams O, Vega-Garcia N, Rodriguez-Perales S, Segovia JC, Quintana-Bustamante O, Roy A, Meyer C, Marschalek R, Smith AL, Milne TA, Fraga MF, Tejedor JR, Menéndez P. Bueno C, et al. Among authors: cantilena s. Blood. 2023 Nov 16;142(20):1752-1756. doi: 10.1182/blood.2023020858. Blood. 2023. PMID: 37756522
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Cantilena S, Gasparoli L, Pal D, Heidenreich O, Klusmann JH, Martens JHA, Faille A, Warren AJ, Karsa M, Pandher R, Somers K, Williams O, de Boer J. Cantilena S, et al. Clin Transl Med. 2022 Jun;12(6):e933. doi: 10.1002/ctm2.933. Clin Transl Med. 2022. PMID: 35730653 Free PMC article.
Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
Clesham K, Walf-Vorderwülbecke V, Gasparoli L, Virely C, Cantilena S, Tsakaneli A, Inglott S, Adams S, Samarasinghe S, Bartram J, Williams G, de Boer J, Williams O. Clesham K, et al. Among authors: cantilena s. Leukemia. 2022 Jun;36(6):1541-1549. doi: 10.1038/s41375-022-01554-9. Epub 2022 Apr 2. Leukemia. 2022. PMID: 35368048 Free PMC article.
Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.
Meier S, Cantilena S, Niklison Chirou MV, Anderson J, Hargrave D, Salomoni P, de Boer J, Michod D. Meier S, et al. Among authors: cantilena s. Cell Death Dis. 2021 Aug 11;12(8):785. doi: 10.1038/s41419-021-04078-9. Cell Death Dis. 2021. PMID: 34381018 Free PMC article.
FDA-approved disulfiram as a novel treatment for aggressive leukemia.
Karsa M, Xiao L, Ronca E, Bongers A, Spurling D, Karsa A, Cantilena S, Mariana A, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Sutton R, Lock RB, Williams O, de Boer J, Haber M, Norris MD, Henderson MJ, Somers K. Karsa M, et al. Among authors: cantilena s. J Mol Med (Berl). 2024 Apr;102(4):507-519. doi: 10.1007/s00109-023-02414-4. Epub 2024 Feb 13. J Mol Med (Berl). 2024. PMID: 38349407 Free PMC article.
A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.
Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P. Dvorkina M, et al. Among authors: cantilena s. Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Clin Cancer Res. 2016. PMID: 27076624
12 results